



ASX Announcement and Media Release

27 June 2018

SciGen Ltd

RESULTS OF ANNUAL GENERAL MEETING

1. Annual General Meeting

SciGen Ltd (the “Company”) wishes to advise that all resolutions contained in the Notice of Annual General Meeting were duly voted on in accordance with Section 251 AA of the Corporations Act 2001 and ASX Listing Rule 3.13.2.

The following information is provided in relation to the resolutions considered by shareholders at the Annual General Meeting held on 27 June 2018 at 9.30 a.m. Singapore time (11.30 a.m. AEST) in Singapore.

RESOLUTION	DESCRIPTION	FOR	AGAINST	ABSTAIN	RESULT
1	Adoption of the Audited Accounts – 31 December 2017	527,792,147	-	20,496	CARRIED
2	Re-election of Mr Adam Tomasz Polonek	527,792,147	-	20,496	CARRIED
3	Re-election of Mr Marcin Dukaczewski	5,259	527,786,888	20,496	NOT CARRIED
4	Re-election of Mr Mateusz Patryk Kosecki	5,412	527,786,735	20,496	NOT CARRIED
5	Re-election of Ms Yvonne Lim Lean Guat	527,792,147	-	20,496	CARRIED
6	Re-Appointment of Auditors	527,792,147	-	20,496	CARRIED
7	Directors' Remuneration – 31 December 2017	527,787,994	20,496	4,153	CARRIED

As a result of Resolutions 3 and 4, Messrs Marcin Dukaczewski and Mateusz Patryk Kosecki will cease to be directors of the Company with effect from 27 June 2018.

2. Responsibility Statement

The Directors (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and opinions expressed in this announcement are fair and accurate, and that there are no other material facts not contained in this announcement, the omission of which would make any statement in this announcement misleading, and they jointly and severally accept responsibility accordingly. Where any information has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the Directors has been to ensure through reasonable enquiries that such information is accurately extracted from such sources or, as the case may be, reflected or reproduced in this announcement.

BY ORDER OF THE BOARD

For and on behalf of SciGen Ltd

Marek Dziki

27 June 2018

About SciGen

SciGen Ltd (“SciGen”) is a biopharmaceutical company involved in sales and marketing of genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of endocrinology, paediatrics, neurology and oncology care.

Its core product portfolio consists of biosimilar products, notably, recombinant human insulin and recombinant human growth hormone which have undergone substantial clinical development. SciGen has since built a diversified portfolio in recent years, comprising neurology, oncology care products, paediatric supplements, orthopaedic injection therapy, anti-hypertensives and a range of medical devices.

SciGen has acquired the rights to distribute and market biopharmaceutical and proprietary products under both exclusive and semi-exclusive licensing arrangements. Its strategy is to focus on biosimilar products which have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen’s current focus is in the Asia Pacific region which provides growth opportunities for its range of products. Following a licensing agreement signed in early 2012, SciGen now has marketing rights for recombinant human insulin in the Middle East and Africa. SciGen’s contract manufacturer for recombinant human insulin is its ultimate holding company in Poland, Bioton S.A..

SciGen currently maintains internal sales and marketing teams at its subsidiary offices, whilst venturing into distribution partnerships in other markets. Through joint collaboration with its partners, SciGen uses its extensive expertise in regulatory and clinical environments, to cater to a broader spectrum of market.

SciGen was established in 1988, as a Singapore biopharmaceutical company. SciGen is listed on the Australian Stock Exchange (ASX code SIE). Its corporate headquarters is located in Singapore, with subsidiary offices in Australia, South Korea, China and a sales office in Philippines. Strategic distribution channels are present in Thailand, Hong Kong, Pakistan, Indonesia, Singapore, Bangladesh, Myanmar and Vietnam.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Adam Polonek CFO SciGen Ltd +65 6779 6638